Malignant Melanoma, with emphasis on first relapse cases  by Hafez, Kevin K. & MacCormick, Ronald
Journal of Taibah University Medical Sciences (2012) 7(2), 81–86Taibah University
Journal of Taibah University Medical Sciences
www.jtaibahumedsc.net
www.sciencedirect.comClinical StudyMalignant Melanoma, with emphasis on ﬁrst relapse casesKevin K. Hafez, FCFP a,* and Ronald MacCormick, FRCPC ba Enhanced Skills Residency Program, Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada
b Cape Breton Cancer Centre, Cape Breton Regional Hospital, Sydney, Nova Scotia, CanadaReceived 13 September 2012; revised 1 November 2012; accepted 28 November 2012*
de
C
(4
E
Pe
16
htKEYWORDS
Acral;
Breslow method;
Clark method;
Lentigo maligna;
Lentiginous or unclassiﬁed
melanoma;
Nodular;
Radial superﬁcial spreading;
Systemic recurrence;
Therapeutic lymph node
dissectionCorresponding author: Ac
ncy Program, Department
algary, Calgary, Alberta, Can
03) 476 8784.
-mail address: hafez@ucalga
er review under responsibilit
Production an
58-3612 ª 2012 Taibah Univ
tp://dx.doi.org/10.1016/j.jtumting Dir
of Fam
ada. Tel
ry.ca (K
y of Taib
d hostin
ersity. P
ed.2012.Abstract Objectives: Malignant melanoma is the eighth most commonly diagnosed malignancy in
Nova Scotia, Canada. The incidence of and death from malignant melanoma are increasing, despite
surgical resection of lesions. The risk for local recurrence after treatment is 3.2%. Our aim was to
determine the characteristics of malignant melanoma and the risk for relapse in an industrial region
of Nova Scotia.
Methods: We performed a retrospective analysis of the records of 90% of all melanoma patients
in 1999–2010 in Cape Breton, Nova Scotia (N= 100). Data were derived from the patients’ medical
records kept at the Cape Breton District Health Authority.
Results: Of the 100 cases of malignant melanoma, 57 were in men and 43 were in women.
Treatment consisted of local excision for 91 patients, therapeutic lymph node dissection for 5
and no treatment for 2. Relapses occurred in 16 patients (10 men, 6 women) between 2003 and
2010. Eleven of the 16 patients with relapses (69%) were alive at 1 year, four (25%) at 2 years
and three (19%)] at 5 years. The majority, 80/100, of patients are still alive without malignant
melanoma, while two patients are alive but with malignant melanoma. Of the 18 patients who died,
eight died from malignant melanoma.
Conclusions: We obtained a better 5-year survival rate (82%) than that reported in the literature
(73%). In Cape Breton, more men than women have malignant melanoma and are more likely to
have local recurrence. The long-term survival rate after relapse was poor.
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11.005Introduction
The incidence of malignant melanoma is increasing dramati-
cally among people with light-coloured skin in all parts of
the world, and the incidence is increasing faster than that of
any other cancer.1 The rate of death from melanoma is also
increasing, despite the improved survival associated with early
surgical removal of lesions. In 1935, for example, one in 1500
Americans developed malignant melanoma; melanoma now
occurs in one of every 50 Americans, particularly among males
aged 15–35, for whom it is among the leading causes of death
from cancer.2 Worldwide, the incidence varies from a high of
28.4 per 100000 in Australia to 0.2 per 100000 in Japan.3Ltd. All rights reserved.
Figure 1: Patients’rate as per Clark’s staging.
Figure 2: Patients’rate as per Breslow’s staging.
Figure 3: Types of treatment for all patients.
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treatment is 3.2%,4,5 and the risk for systemic recurrence de-
pends on the depth of penetration.6
Malignant melanoma is the eighth most commonly diag-
nosed malignancy in Nova Scotia, Canada,7 accounting for
3% of all cancers.2 Despite awareness of the high incidence
rates of various cancers among people in Cape Breton, there
are no published data on either the occurrence or the recur-
rence of malignant melanoma. The purpose of our study was
to assess the Cape Breton experience of malignant melanoma
with an emphasis on ﬁrst relapse cases.
Materials and Methods
We conducted a retrospective analysis of cases of malignant
melanoma between January 1999 and October 2010. All data
were derived from hospital charts from the Department of
Medical Records, which contains data on 100 of all 113 pa-
tients with malignant melanoma in the four hospitals in indus-
trial Cape Breton, in Sydney, North Sydney, Glace Bay and
NewWaterford. These hospitals are the main referral hospitals
for rural Cape Breton.
The 113 patients identiﬁed from the Nova Scotia Cancer
Registry database for Cape Breton had one of the ﬁve forms
of malignant melanoma: radial (superﬁcial) spreading, lentigo
maligna, nodular, acral lentiginous or unclassiﬁed melanoma.
Thirteen patients (10%) were excluded because the reports
were inconsistent, incomplete or unreadable, leaving 100 pa-
tients for analysis. Demographic data were obtained.
As comorbidity signiﬁcantly inﬂuences the survival of pa-
tients with melanoma,5 the effect of coexisting conditions
was examined by consulting outpatient records and discharge
summaries. The comorbid conditions were naevus, non-mela-
noma skin malignancy, other malignancy and non-melanoma
causes such as cardiac conditions, peripheral vascular disease,
cerebrovascular ischaemia, chronic obstructive pulmonary dis-
ease, gastrointestinal disease and liver disease.
The location of the tumour was determined, as it can affect
survival and recurrence rate.6 Clark’s method of microstaging
malignant melanoma, which is based on a qualitative descrip-
tion of increasing levels of penetration through the dermis to
the subcutaneous fat, was used. We also used the Breslow
microstaging method, in which an ocular micrometer is used
to quantify the vertical depth of invasion (in mm) from the
granular layer of the epidermis (or the base of an ulcer) to
the deepest identiﬁable contiguous melanoma cell.6
Sixteen patients were found to have relapsed over the 7-year
period 2003–2010. We examined the relapse characteristics and
comorbid conditions of these 16 patients.
Survival time was calculated from the date of ﬁrst relapse to
the date on which the data were censored or the date of death
from melanoma or from any cause. Data were censored if a pa-
tient underwent therapy, was still alive at the end of the study
or was lost to follow-up. Survival analysis was performed for
patients who relapsed, died or survived.
Results
One hundred patients with malignant melanoma were followed
up for 11 years. Of these, 57 were men and 43 were women,
with a mean age of 60.3 years (range, 17–92 years) They wereall white. Within the Cape Breton area, 79 patients were from
Sydney, 10 from North Sydney, 9 from Glace Bay and 2 from
New Waterford.
Ten patients had a pre-existing naevus in the same location,
and 15 had had other skin malignancies (basal cell or squa-
mous cell carcinoma) at various locations.
Tumour characteristics
The location of malignant melanoma was on the extremities in
39 cases, the trunk in 34 cases, the head and neck region in 22
cases and lymph nodes in 5 cases. Primary malignant mela-
noma was diagnosed in 95 cases, and 5 cases were metastatic.
Figure 1 shows the tumour staging according to Clark’s le-
vel of penetration: 29 patients had stage I tumours above intact
basal lamina, 22 had stage II tumours reaching the papillary–
reticular dermis interface, 18 had stage III tumours invading
the papillary dermis, 13 had stage IV tumours invading the
reticular dermis, and 3 patients had stage V tumours invading
the subcutaneous fat. The remaining 15 patients had tumours
Figure 5: Age distribution.
Figure 6: Time and rate of ﬁrst relapse cases.
Malignant Melanoma, with emphasis on ﬁrst relapse cases 83of unknown stage, because of mixed cell type, metastasis
favouring malignant melanoma, primary tumour in a lymph
node or no speciﬁc staging report.
Figure 2 shows the tumour staging according to Breslow
depth of invasion. In 26 patients, the tumour was classiﬁed
as 0 (granular layer of epidermis), 25 patients had tumours
>0 but <0.76 mm, 17 tumours were >0.76 mm but
<0.50 mm, 10 were >1.51 mm but <4 mm, 2 were >4 mm,
and the remaining 20 patients were classiﬁed as ‘unknown’.
Treatment
Figure 3 summarizes the therapeutic approach, which varied
considerably, depending on the location and depth of the pri-
mary lesion. Local excision was used for 91 patients, therapeu-
tic lymph node dissection for 5 patients, chemotherapy for 2
patients, and 2 patients received no treatment. Further thera-
peutic interventions were carried out for 78 of the 91 patients
who underwent local excision: wide re-excision was required
for 70 patients, additional prophylactic lymph node dissection
for 3 patients, further therapeutic lymph node dissection for 2
patients and chemotherapy for 3 patients.
Outcomes
Figure 4 shows the outcomes: 16 cases of relapse and 84 cases
of non-relapse. Of the patients who relapsed, 10 were men and
6 were women aged 29–79 years. Figure 5 shows the age distri-
bution of these ﬁrst-relapse cases. Two patients had a pre-
existing naevus in the same location, and three had had a basal
cell or squamous cell carcinoma at various locations. Figure 6
shows the timing of the relapses. Two occurred within
<1 year, six occurred within 1 year, four within 2 years, two
within 3 years and 1 within 5 years.
Figure 7 shows the tumour staging of the relapses according
to Clark’s level of penetration. Seven were classiﬁed as ‘un-
known’; two were stage II, four were stage III, two were stage
IV, and one was stage V. Figure 8 shows the tumour staging
according to Breslow depth of invasion. Eight were classiﬁed
as ‘unknown’, one was <0.76 mm, two were 0.76–1.50 mm,
and ﬁve were 1.51–4 mm.
The treatment given, according to the site of relapse, is
shown in Figure 9. All six patients with local relapses under-
went local wide excision; four of the six patients with regional
relapses were treated by node dissection only and two by node
dissection and chemotherapy. Three of four patients with dis-Figure 4: Relapse and non-relapse cases.tant relapses were treated with chemotherapy, and the other
received palliative care.Figure 7: Clark’s staging of ﬁrst relapse cases.
Figure 8: Breslow’s staging of ﬁrst relapse cases.
Figure 9: Treatment of ﬁrst relapse cases as per different sites.
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1 year, four (25%) were alive at 2 years, and three (19%) were
alive at 5 years.
The majority, 80/100, patients are still alive without malig-
nant melanoma, while two patients are alive but with malig-
nant melanoma. Of the 18 patients who died, eight died
from malignant melanoma.
Discussion
Of the 100 patients with malignant melanoma between 1999
and 2010, 16 developed local, regional or distal recurrence.
Of these, 11 survived for 1 year and four for 2 years. The local
recurrence rate was very high, 6%, whereas reports from other
countries such as the United States give a rate of only 3.2%.5
The rate may be increased by thickness >4 mm (13%),8 ulcer-
ation (11.5%),4 and face, scalp, hand or foot location (5–
12%).9 Older patients tend to have a worse prognosis,10,11
and we found that 13/16 relapses were in patients P50 years
of age. It is unclear, however, why our local recurrence rate
was so high. The American Physicians Data Query Cancer
Information File (an online database) shows that local recur-
rence and subsequent metastasis largely depend on tumour
thickness. Although the risk for systemic (lymph node and dis-
tant) recurrence depends on the depth of penetration by Bre-
slow staging, we were unable to estimate the risk accurately
because of the large number of ‘unknowns’: in 20% and
50% of primary and relapse cases, respectively. Furthermore,
13 patients with malignant melanoma were excluded because
of inconsistent, incomplete or unreadable records.
There appears to be an association between certain pre-
existing pigmented skin lesions and cutaneous melanoma.
The National Institutes of Health Conference concluded that
melanoma may arise de novo12 or in association with pre-exist-
ing melanocytic naevi.13 The pre-existing lesions include dys-
plastic naevi, congenital naevi and common acquired naevi.
The lifetime risk of melanoma may approach 100% for people
with dysplastic naevi who are from melanoma-prone fami-
lies,14,15 and the lifetime risk for melanoma in patients with
large congenital naevi has been estimated at 5–20%.16 The ex-
tent to which melanoma develops in smaller congenital naevi is
unclear;17 the incidence has been reported to be increased,18
but the magnitude of that increase is not well established. In
our series, pre-existing melanocytic naevi were found in 10%of all patients and two of 16 who had relapses; and 15% of
all patients and 3/16 relapse cases had had basal cell or squa-
mous cell carcinoma at some time previously. It is unclear
whether there is an association between other skin malignan-
cies and melanoma; however, most of the risk factors (older
age, sex, race) are the same.19
Although our study suggests that melanoma can develop in
people of all ages and both sexes, all the patients were white, as
very few people of other races live in Cape Breton. It has been
reported that melanoma affects all races, although the risk of
whites is 17 times greater than that for blacks,20 for example.
The only effective therapy for melanoma is surgical resec-
tion;21,22 however, several European reports suggest that
superﬁcial contact X-ray therapy at extremely high doses
(>10000 cGy) with rapid fall-off (over 50% at 1 mm) may
be indicated for large, superﬁcial lesions in critical cases23
(e.g. lentigo maligna melanoma of the head and neck). Other
reports suggested that both radiotherapy and regional hyper-
thermic limb perfusion can be used for palliative treatment
of metastases24,25 (e.g. cerebral, bone) and for local recurrences
of melanoma of the lower extremities.26,27 In our study, none
of the patients with primary malignant melanoma or relapse
received any form of radiotherapy or hyperthermic limb perfu-
sion. In fact, according to the Nova Scotia Cancer Registry
electronic database, only 5% (23/463) of new melanoma pa-
tients diagnosed in Nova Scotia between 2006 and 2009 re-
ceived radiotherapy for this disease. The rates of
radiotherapy use in other Canadian provinces are much lower
than the accepted national and international targets and lower
than rates reported from other jurisdictions.28 The highest
rates were recorded in communities close to radiotherapy cen-
tres.28 This, in addition to the very low rates of radiotherapy
use in Nova Scotia, may explain why radiotherapy is rarely
used for malignant melanoma in Cape Breton.
According to the Canadian Cancer Statistics7, the incidence
rate of malignant melanoma in women has been decreasing
since the 1970s but increasing in men during the same period.
The estimated average annual percentage change for 1999–
2009 was 0.9% among men and –0.3% among women. The
corresponding values for Nova Scotia were 2.2% for men
and –0.4% for women. Neither trend was statistically signiﬁ-
cant. For Cape Breton county, the average annual percentage
change for women was 1.8% (not decreasing but not signiﬁ-
cantly different from zero) and that for men was 7.3%, which
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iation because of the small number of cases seen. Nova Scotia
has higher rates of melanoma than Canada and has had for
some time (currently about 30% higher). Although there
may have been a decrease in the 1970s and early 1980s in the
incidence of melanoma in women, the evidence for a recent de-
crease in women is weak in Canada and weak or nonexistent in
Nova Scotia. There is somewhat more evidence of an upward
trend in the incidence among men in recent years (in both Can-
ada and Nova Scotia), but the evidence can be described as
‘weak’ at best.
Our study explains neither the high incidence nor the high
local recurrence rate of malignant melanoma in Cape Breton.
We found that, despite the high incidence of malignant mela-
noma and irrespective of the level or depth of the primary le-
sion, the 5-year survival rate was 82% for patients with
pathologically negative lymph nodes. A 5-year survival rate
of 73% has been reported.29,30 The higher rate in our study
can be ascribed to early detection and surgical excision of early
primary lesions.
Conclusion
We conclude that people (men more than women) in Cape Bre-
ton have a high incidence of malignant melanoma, a high local
recurrence rate and poor long-term survival after relapse. Our
ﬁndings indicate the need for a clinical practice guideline and
more aggressive strategies for the prevention, treatment and
follow-up of patients with malignant melanoma and those with
precancerous pigmented lesions.
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